多巴胺D2和腺苷酸受体A2A：在治疗帕金森综合症的历史、当前与未来。

Title:The Dopamine D₂ and Adenosine A_2A Receptors: Past, Present and Future Trends for the Treatment of Parkinson's Disease

Volume: 21 Issue: 27

Author(s): M. Jorg, P.J. Scammells and B. Capuano

Affiliation:

关键词: 腺苷酸A2A受体拮抗剂，二价配位体，多巴胺，多巴胺D2受体拮抗剂，G蛋白偶联受体，左旋多巴，非多巴胺能药物，帕金森氏病

摘要: Herein, we present an overview of the historic development of drugs for the treatment of Parkinson’s disease as well as prospective novel treatment forms based on targeting the dopamine and adenosine receptors. The review includes the development of levodopa, a precursor of the neurotransmitter dopamine, which to date is the most commonly prescribed and most effective drug for controlling the motor symptoms of Parkinson's disease, to more recent studies of the adenosine receptor; a promising target for the treatment of Parkinson’s disease due to its intrinsic neuroprotective nature. Ongoing and future drug-based research on the dopamine and adenosine receptors has the advantage of being guided by the improved understanding of receptor topography as well as their functional roles. Breakthroughs such as the first ligand-bound X-ray structure of a selective adenosine A_2A receptor antagonist in complex with the adenosine A_2A receptor, the discovery of the existence of dopamine D₂ homodimers, dopamine D₂- adenosine A_2A heterodimers and higher order oligomers in addition to technological progress have changed the direction of research in academia and industry and form the pillars for novel and exciting discoveries in this field.

Cite this article as:

Jorg M., Scammells P.J. and Capuano B., The Dopamine D₂ and Adenosine A_2A Receptors: Past, Present and Future Trends for the Treatment of Parkinson's Disease, Current Medicinal Chemistry 2014; 21 (27) . https://dx.doi.org/10.2174/1389200215666140217110716